NGM282 Significantly Reduces Hepatic Steatosis Independent of Type 2 Diabetes (T2D) Status or Statin Usage—Results from a Phase 2 Trial in Patients with Nonalcoholic Steatohepatitis (NASH)
DEPAOLI, ALEX, ROSSI, STEPHEN J., LING, LEI, HARRISON, STEPHEN A., ABDELMALEK, MANAL F., JAROS, MARK R., SOMARATNE, RANSI
Published in Diabetes (New York, N.Y.) (01.07.2018)
Published in Diabetes (New York, N.Y.) (01.07.2018)
Get full text
Journal Article